دورية أكاديمية
Genetic Characterization Conferred Co-Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis Isolates from Southern Xinjiang, China.
| العنوان: | Genetic Characterization Conferred Co-Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis Isolates from Southern Xinjiang, China. |
|---|---|
| المؤلفون: | Cao B; School of Public Health, University of South China, Hengyang, 421001, People's Republic of China.; State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, People's Republic of China., Mijiti X; The Eighth Affiliated Hospital of Xinjiang Medical University, Urumqi, 830000, People's Republic of China., Deng LL; State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, People's Republic of China.; National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China., Wang Q; The Eighth Affiliated Hospital of Xinjiang Medical University, Urumqi, 830000, People's Republic of China., Yu JJ; School of Public Health, University of South China, Hengyang, 421001, People's Republic of China.; State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, People's Republic of China., Anwaierjiang A; College of Xinjiang Uyghur Medicine, Hetian, 848000, People's Republic of China., Qian C; State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, People's Republic of China.; Wenzhou Key Laboratory of Sanitary Microbiology, Key Laboratory of Laboratory Medicine, Ministry of Education, China, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, People's Republic of China., Li M; State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, People's Republic of China., Fang DA; State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, People's Republic of China.; Wenzhou Key Laboratory of Sanitary Microbiology, Key Laboratory of Laboratory Medicine, Ministry of Education, China, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, People's Republic of China., Jiang Y; State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, People's Republic of China., Zhao LL; State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, People's Republic of China., Zhao X; State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, People's Republic of China., Wan K; State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, People's Republic of China., Liu H; State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, People's Republic of China., Li G; State Key Laboratory for Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, People's Republic of China., Yuan X; School of Public Health, University of South China, Hengyang, 421001, People's Republic of China. |
| المصدر: | Infection and drug resistance [Infect Drug Resist] 2023 May 19; Vol. 16, pp. 3117-3135. Date of Electronic Publication: 2023 May 19 (Print Publication: 2023). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Dove Medical Press Country of Publication: New Zealand NLM ID: 101550216 Publication Model: eCollection Cited Medium: Print ISSN: 1178-6973 (Print) Linking ISSN: 11786973 NLM ISO Abbreviation: Infect Drug Resist Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Auckland, N.Z. : Dove Medical Press, 2008- |
| مستخلص: | Background: Ethionamide (ETH), a structural analogue of isoniazid (INH), is used for treating multidrug-resistant tuberculosis (MDR-TB). Due to the common target InhA, INH and ETH showed cross-resistance in M. tuberculosis . This study aimed to explore the INH and ETH resistant profiles and genetic mutations conferring independent INH- or ETH-resistance and INH-ETH cross-resistance in M. tuberculosis circulating in south of Xinjiang, China. Methods: From Sep 2017 to Dec 2018, 312 isolates were included using drug susceptibility testing (DST), spoligotyping, and whole genome sequencing (WGS) to analyze the resistance characteristics for INH and/or ETH. Results: Among the 312 isolates, 185 (58.3%) and 127 (40.7%) belonged to the Beijing family and non-Beijing family, respectively; 90 (28.9%) were INH-resistant (INH R ) with mutation rates of 74.4% in katG , 13.3% in inhA and its promoter, 11.1% in ahpC and its upstream region, 2.2% in ndh , 0.0% in mshA , whilst 34 (10.9%) were ETH-resistant (ETH R ) with mutation rates of 38.2% in ethA , 26.2% in inhA and its promoter, and 5.9% in ndh , 0.0% in ethR or mshA ; and 25 (8.0%) were INH-ETH co-resistant (INH R ETH R ) with mutation rates of 40.0% in inhA and its promoter, and 8% in ndh. katG mutants tended to display high-level resistant to INH; and more inhA and its promoter mutants showed low-level of INH and ETH resistance. The optimal gene combinations by WGS for the prediction of INH R , ETH R , and INH R ETH R were, respectively, katG + inhA and its promoter (sensitivity: 81.11%, specificity: 90.54%), ethA + inhA and its promoter+ ndh (sensitivity: 61.76%, specificity: 76.62%), and inhA and its promoter+ ndh (sensitivity: 48.00%, specificity: 97.65%). Conclusion: This study revealed the high diversity of genetic mutations conferring INH and/or ETH resistance among M. tuberculosis isolates, which would facilitate the study on INH R and/or ETH R mechanisms and provide clues for choosing ETH for MDR treatment and molecular DST methods in south of Xinjiang, China. Competing Interests: We have no conflicts of interest to declare. (© 2023 Cao et al.) |
| References: | J Infect Dis. 2000 Dec;182(6):1788-90. (PMID: 11069256) Science. 1994 Jan 14;263(5144):227-30. (PMID: 8284673) J Antimicrob Chemother. 2013 Aug;68(8):1728-32. (PMID: 23539241) J Biol Chem. 2000 Sep 8;275(36):28326-31. (PMID: 10869356) Nat Genet. 2014 Mar;46(3):279-86. (PMID: 24464101) Antimicrob Agents Chemother. 2009 Aug;53(8):3181-9. (PMID: 19451293) Mol Microbiol. 2004 Jan;51(1):175-88. (PMID: 14651620) Antimicrob Agents Chemother. 2005 Feb;49(2):708-20. (PMID: 15673755) J Biol Chem. 2002 Apr 12;277(15):12824-9. (PMID: 11823459) Antimicrob Agents Chemother. 2011 Jan;55(1):355-60. (PMID: 20974869) Clin Microbiol Infect. 2022 May;28(5):731.e9-731.e15. (PMID: 34600118) N Engl J Med. 2010 Sep 9;363(11):1005-15. (PMID: 20825313) PLoS One. 2018 May 30;13(5):e0198091. (PMID: 29847567) Biochemistry. 2006 Apr 4;45(13):4131-40. (PMID: 16566587) J Clin Microbiol. 2019 Jan 2;57(1):. (PMID: 30404943) Antimicrob Agents Chemother. 2015 Dec;59(12):7805-10. (PMID: 26369965) Antimicrob Agents Chemother. 2003 Dec;47(12):3799-805. (PMID: 14638486) J Clin Microbiol. 2013 Jul;51(7):2220-4. (PMID: 23658272) Lancet Infect Dis. 2022 Feb;22(2):242-249. (PMID: 34627496) Int J Mycobacteriol. 2016 Dec;5 Suppl 1:S36-S37. (PMID: 28043598) Emerg Microbes Infect. 2015 Jul;4(7):e42. (PMID: 26251830) J Clin Microbiol. 1997 Apr;35(4):907-14. (PMID: 9157152) Antimicrob Agents Chemother. 2001 Jul;45(7):2157-9. (PMID: 11408244) Antimicrob Agents Chemother. 2002 May;46(5):1417-24. (PMID: 11959577) Antimicrob Agents Chemother. 2014;58(1):364-9. (PMID: 24165186) Microbiol Mol Biol Rev. 2008 Sep;72(3):471-94. (PMID: 18772286) Microbiol Spectr. 2014 Aug;2(4):MGM2-0014-2013. (PMID: 26104204) Lancet Microbe. 2023 Jan;4(1):e20. (PMID: 36521512) Front Microbiol. 2021 Dec 06;12:743198. (PMID: 34938276) Curr Opin Pulm Med. 2011 May;17(3):134-41. (PMID: 21415753) Clin Microbiol Infect. 2018 Jun;24(6):604-609. (PMID: 29108952) Tuber Lung Dis. 2000;80(1):47-56. (PMID: 10897383) Int J Tuberc Lung Dis. 2016 Aug;20(8):1099-104. (PMID: 27393546) Nat Med. 2006 Sep;12(9):1027-9. (PMID: 16906155) Nature. 1998 Jun 11;393(6685):537-44. (PMID: 9634230) J Clin Microbiol. 2002 Mar;40(3):988-95. (PMID: 11880428) Microorganisms. 2022 Jul 15;10(7):. (PMID: 35889155) J Glob Antimicrob Resist. 2018 Dec;15:239-245. (PMID: 30130640) Nat Rev Microbiol. 2019 Sep;17(9):533-545. (PMID: 31209399) J Clin Microbiol. 2008 Jul;46(7):2263-8. (PMID: 18508939) Mol Microbiol. 2004 Jun;52(5):1291-302. (PMID: 15165233) Microbiol Spectr. 2022 Feb 23;10(1):e0154321. (PMID: 35171016) Lancet Microbe. 2022 Apr;3(4):e265-e273. (PMID: 35373160) Methods Enzymol. 1994;235:196-205. (PMID: 8057895) J Bacteriol. 2000 Jul;182(14):4059-67. (PMID: 10869086) Clin Microbiol Infect. 2019 Aug;25(8):1041.e1-1041.e7. (PMID: 30583053) Nature. 1992 Aug 13;358(6387):591-3. (PMID: 1501713) Front Microbiol. 2013 Jul 23;4:208. (PMID: 23888158) J Clin Microbiol. 2006 Oct;44(10):3659-64. (PMID: 17021094) Microbiol Spectr. 2023 Mar 6;:e0276122. (PMID: 36877052) Infect Immun. 2002 Sep;70(9):4955-60. (PMID: 12183541) N Engl J Med. 2001 Jul 19;345(3):170-4. (PMID: 11463011) |
| فهرسة مساهمة: | Keywords: Mycobacterium tuberculosis; cross-resistance; ethionamide; isoniazid; mutation |
| تواريخ الأحداث: | Date Created: 20230525 Latest Revision: 20230528 |
| رمز التحديث: | 20230528 |
| مُعرف محوري في PubMed: | PMC10204763 |
| DOI: | 10.2147/IDR.S407525 |
| PMID: | 37228658 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher 
Full Text Finder | تدمد: | 1178-6973 |
|---|---|
| DOI: | 10.2147/IDR.S407525 |